EU/3/15/1457: Orphan designation for the treatment of tenosynovial giant cell tumour, localised and diffuse type
[5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-trifluoromethyl-pyridin-3-ylmethyl)-amine hydrochloride
Table of contents
Overview
On 19 March 2015, orphan designation (EU/3/15/1457) was granted by the European Commission to Daiichi Sankyo Development Ltd, United Kingdom, for [5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-trifluoromethyl-pyridin-3-ylmethyl)-amine hydrochloride for the treatment of tenosynovial giant cell tumour, localised and diffuse type.
Please note that this product was withdrawn from the Union Register of orphan medicinal products in February 2022 on request of the Sponsor.
Key facts
Active substance |
[5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-trifluoromethyl-pyridin-3-ylmethyl)-amine hydrochloride
|
Intended use |
Treatment of tenosynovial giant cell tumour, localised and diffuse type
|
Orphan designation status |
Withdrawn
|
EU designation number |
EU/3/15/1457
|
Date of designation |
19/03/2015
|
Sponsor |
Daiichi Sankyo Development Ltd
Chiltern Place Chalfont Park Gerrards Cross Buckinghamshire SL9 0BG United Kingdom Tel. +44 (0)1753 893 600 Fax +44 (0)1753 899 107 E-mail: info@dsd-eu.com |
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: